Retinoblastoma protein partners
The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
Studies of the retinoblastoma gene (Rb) have shown that its protein product (pRb) acts to restrict cell proliferation, inhibit apoptosis, and promote cell differentiation. The frequent mutation of the Rb gene, and the functional inactivation of pRb in tumor cells, have spurred interest in the mechanism of pRb action. Recently, much attention has focused on pRb's role in the regulation of the E2F transcription factor. However, biochemical studies have suggested that E2F is only one of many pRb-targets and, to date, at least 110 cellular proteins have been reported to associate with pRb. The plethora of pRb-binding proteins raises several important questions. How many functions does pRb possess, which of these functions are important for development, and which contribute to tumor suppression? The goal of this review is to summarize the current literature of pRb-associated proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RB is now viewed as a transcriptional co-factor that can bind to and either antagonize or potentiate the function of numerous transcription factors11,12.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [11]
In the citing paper
“RB promotes the differentiation of multiple lineages by binding and regulating tissue-specific transcription factors11,42 and inhibitors of differentiation such as ID2 and EID1 (REFS 62–65), as well as general transcription factors and chromatin modifiers66,67.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [11]
Citations
Cites
Items 201–208 of 208
Tamami, M., Lindholm, P. F., & Brady, J. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24551 · Cited by 17
Cziepluch, C., Wenzel, A., Schürmann, J., & Schwab, M. (1993) · PubMed · Cited by 15
Puntoni, F., & Villa-Moruzzi, E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1800 · Cited by 14
Otterson, G. A., Kratzke, R. A., Lin, A. Y., Johnston, P. G., & Kaye, F. J. (1993) · PubMed · Cited by 13
Yamane, K., Katayama, E., Sugasawa, K., & Tsuruo, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203528 · Cited by 11
Interaction of Retinoblastoma Gene Product with Transcription Factors ATFa and ATF2
Gong, Q. Q., Huang, Z., & Wicks, W. D. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1315 · Cited by 7
Tumor suppressors: from genes to function and possible therapies
Helin, K., & Peters, G. G. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(97)01341-3 · Cited by 7
A Novel Link Between REC2, a DNA Recombinase, the Retinoblastoma Protein, and Apoptosis
Fan, G., Ma, X., Kren, B. T., Rice, M. C., Kmiec, E. B., & Steer, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19413 · Cited by 6
Research works printed but not linked: 66
- Abbondanza, 2000, 97, 3130
- Adnane, 1995, Oncogene, 10, 381
- Akiyama, 1992, 89, 7900
- Alberts, 1993, 90, 388
- Aprelikova, 1999, 96, 11866
- Batsche, 1994, Oncogene, 9, 2235
- Bergemann, 1992, Mol. Cell Biol., 12, 1257
- Bergemann, 1992, Mol. Cell Biol., 12, 5673
- Bhat, 1999, 96, 7859
- Brehm, 1998, Nature, 391, 591, 10.1038/35404 · DOI · Paper page
- Buyse, 1995, 92, 4467
- Chang, 1997, 94, 9040
- Chauhan, 1999, Cancer Res., 59, 1192
- Chen, 1994, Mol. Cell Biol., 14, 4380
- Chen, 1996, 93, 465
- Chen, 1995, Cell Growth Differ., 6, 199
- Craven, 1995, Cancer Res., 55, 3969
- Cress, 1993, Mol. Cell Biol., 13, 6314
- Cvekl, 1999, Invest. Ophthalmol. Vis. Sci., 40, 1343
- Cziepluch, 1993, Oncogene, 8, 2833
- Dick, 2000, Mol. Cell Biol., 20, 3715, 10.1128/MCB.20.10.3715-3727.2000 · doi:10.1128/mcb.20.10.3715-3727.2000 · Paper page
- Eberhard, 1999, Cancer Res., 59, 1716s
- Ezhevsky, 1997, 94, 10699
- Fajas, 2000, 97, 7738
- Fattaey, 1993, Oncogene, 8, 3149
- Ferreira, 1998, 95, 10493
- Hagemeier, 1993, 90, 1580
- Hall, 1993, Oncogene, 8, 1377
- He, 2000, Oncogene, 19, 3233
- Horton, 1995, Cell Growth Differ., 6, 395
- Hu, 1992, Mol. Cell Biol., 12, 971
- Ivey-Hoyle, 1993, Mol. Cell Biol., 13, 7802
- Kelly, 1998, 95, 2535
- Kennedy, 2000, Genes Dev.
- Kim, 1991, 88, 3052
- Kim, 1994, Mol. Cell Biol., 14, 7256
- Kitagawa, 1992, Oncogene, 7, 1067
- Knudson, 1971, 68, 820
- Lees, 1993, Mol. Cell Biol., 13, 7813
- Leone, 2000, Mol. Cell Biol., 20, 3626, 10.1128/MCB.20.10.3626-3632.2000 · doi:10.1128/mcb.20.10.3626-3632.2000 · Paper page
- Mancini, 1994, 91, 418
- Martelli, 1994, Oncogene, 9, 3579
- Meloni, 1999, 96, 9574
- Nevins, 1998, Cell Growth Differ., 9, 585
- Nihei, 1993, Cancer Res., 53, 1702
- Nuell, 1991, Mol. Cell Biol., 11, 1372
- Numata, 1999, Cancer Res., 59, 3741
- Otterson, 1993, Oncogene, 8, 949
- Ozaki, 1994, Oncogene, 9, 2649
- Ruggieri, 1989, 86, 8778
- Sellers, 1995, 92, 11544
- Shan, 1992, Mol. Cell Biol., 12, 5620
- Shao, 1995, 92, 3115
- Sterner, 1996, Cell Growth Differ., 7, 53
- Tamrakar, 2000, J. Biol. Chem.
- Templeton, 1992, Mol. Cell Biol., 12, 435443
- Templeton, 1991, 88, 3033
- Trouche, 1997, 94, 11268
- Udvadia, 1993, 90, 3265
- Udvadia, 1995, 92, 3953
- Williams, 1992, Oncogene, 7, 423
- Witte, 1997, 94, 1212
- Wu, 1998, Nucleic Acids Res., 26, 48374845
- Yarden, 1999, 96, 4983
- Yavuzer, 1995, Oncogene, 10, 123
- Zhu, 1997, J. Cell Biochem., 66, 441, 10.1002/(SICI)1097-4644(19970915)66:4<441::AID-JCB3>3.0.CO;2-L · doi:10.1002/(sici)1097-4644(19970915)66:4<441::aid-jcb3>3.0.co;2-l
Cited by
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
“So far, more than 100 RB-binding proteins have been identifie”
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
“Because Rb interacts with well over 100 proteins of various function (88) and because the response to PD 0332991 is tumor specific, sensitivity is likely governed by multiple factors.”
BackgroundCellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
“RB is now viewed as a transcriptional co-factor that can bind to and either antagonize or potentiate the function of numerous transcription factor”
BackgroundMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
“highlighted by the fact that pRb can bind more than 120and Mariano Barbacid1,* cellular proteins (Morris and Dyson, 2001).1Molecular Oncology Program Phosphorylation of pRb by D-type cyclin/Cdk4 orCentro Nacional de Investigaciones Oncológicas (CNIO) Cdk6 complexes results in its partial…”
BackgroundThe retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
“Indeed, RB potentially interacts with more than 100 different cellular protein”
Background
Metadata
- Authors
- Morris, E. J., & Dyson, N. J.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Nicholas J. Dyson
- Venue
- Advances in Cancer Research
- Publisher
- Elsevier
- Published
- 2001
- Volume
- 82
- Pages
- 1-54
- ISSN
- 0065-230X (ISSN-L)
- OpenAlex
- W1486122524
- Cited by
- 349
- References
- 205
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 9 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 13 · 2014: 10 · 2013: 10 · 2012: 16
- FWCI
- 54.26
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Advances in cancer research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Keywords
- retinoblastoma protein, E2F transcription factors, tumor suppression, cell proliferation, apoptosis, cell differentiation, protein-protein interaction, retinoblastoma gene
- MeSH terms
- Carrier Proteins, Humans, Transcription Factors, Retinoblastoma Protein, Genes, Retinoblastoma, Cell Cycle Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.